IDR Data
CMS PUF data · 2023 Q1–2025 Q4

Federal IDR outcomes: Hospitals and facilities in Nevada

In 2025 Q1–Q4, the provider or facility offer prevailed in 97.2% of 10,178 determined Federal IDR dispute line items for hospitals and facilities in Nevada. The median prevailing offer was 2.12x the QPA (25th–75th percentile 1.78x–3.20x; n = 4,399). The median time to a decision was 42 business days (n = 10,178).

Determined line items

10,178

2025 Q1–Q4 · 0 split decisions excluded

Provider win rate

97.2%

n = 10,178 · 2025 Q1–Q4

Median payment vs QPA

2.12x

middle half 1.78x–3.20x · n = 4,399 · 2025 Q1–Q4

Median days to decision

42

business days, from dispute initiation · n = 10,178 · 2025 Q1–Q4

Dollar amounts are not shown for specialty groups: the CMS QPA and Offers file, the only source of dollar figures, has no specialty field. See methodology.

By period

PeriodLine itemsWin %Median ×QPA25th–75thRatio nMedian days
2025 Q1–Q410,17897.2%2.12x1.78x–3.20x4,39942
2024 Q1–Q41,16594.5%2.38x1.64x–4.58x40630
2023 Q1–Q45777.2%1.58x1.18x–2.53x55173
2023 Q1–2025 Q411,40096.8%2.12x1.78x–3.26x4,860not pooled

Line items = determined dispute line items (n). Win rate excludes split decisions and includes default decisions. Ratio n = line items reporting a payment-to-QPA ratio. Days are business days as reported by CMS (2023–2024: from IDR entity assignment; 2025: from initiation) and are never pooled.

Most disputed CPT codes

CPT codeLine itemsWin %Median ×QPARatio nMedian days
36415 Insertion of needle into vein for collection of blood sample49497.4%2.00x7542
85025 Complete blood cell count (red cells, white blood cell, platelets), automated te45397.1%1.91x7141
99285 Emergency department visit with high level of medical decision making37095.7%1.88x33041
80053 Blood test, comprehensive group of blood chemicals30497.7%3.58x4342
93005 Routine electrocardiogram (ECG) using at least 12 leads with tracing25498.0%2.04x4341
99284 Emergency department visit with moderate level of medical decision making18697.8%1.96x17141
96374 Injection of drug or substance into vein18296.7%1.78x15742
83690 Lipase (fat enzyme) level17195.9%–2642
80048 Blood test, basic group of blood chemicals (Calcium, total)16797.0%1.96x3941
71045 X-ray of chest, 1 view16398.2%1.66x12736
84484 Troponin (protein) analysis, quantitative15697.4%–2841
96375 Injection of additional new drug or substance into vein15096.7%2.12x11641
81001 Manual urinalysis test with examination using microscope, automated14296.5%–2543
96361 Infusion into a vein for hydration, each additional hour11597.4%1.77x9743
96372 Injection of drug or substance under skin or into muscle11396.5%–1741
87804 Detection test by immunoassay with direct visual observation for influenza virus9695.8%–1642
84703 Gonadotropin (reproductive hormone) analysis8496.4%–1541
70450 CT scan head or brain without contrast8397.6%7.98x6842
87086 Bacterial colony count, urine6795.5%–742
74177 CT scan of abdomen and pelvis with contrast6396.8%3.20x5244

2025 Q1–Q4 · rows with n ≥ 30 determined line items · sorted by n.

Related: all specialties in Nevada · Hospitals and facilities in all states

FAQ

What is the Federal IDR provider win rate for hospitals and facilities in Nevada?

In 2025 Q1–Q4, the provider or facility offer was selected in 97.2% of 10,178 determined dispute line items for hospitals and facilities in Nevada. Split decisions are excluded from the denominator and default decisions are included. Withdrawn, settled and ineligible disputes are not in the CMS data.

How do Federal IDR payments compare with the QPA for hospitals and facilities in Nevada?

In 2025 Q1–Q4, the median prevailing offer was 2.12x the qualifying payment amount (QPA), with a 25th to 75th percentile range of 1.78x to 3.20x (n = 4,399 line items). This uses the CMS field Prevailing Party Offer as % of QPA, where 1.00x equals the QPA.

How long do Federal IDR decisions take for hospitals and facilities in Nevada?

In 2025 Q1–Q4, the median was 42 business days (n = 10,178 line items), using the CMS field Length of Time to Make Determination (from dispute initiation).

How to Utilize IDR